Research · Source update
ACHIEVE-2 examines Foundayo against dapagliflozin
Source context: Read the linked original research or registry entry for study status and limitations.
A Phase 3 study compared an investigational oral GLP-1 regimen with dapagliflozin in type 2 diabetes. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations.
What prompted this update?
A Phase 3 study compared an investigational oral GLP-1 regimen with dapagliflozin in type 2 diabetes. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations. The originating source is Lilly ACHIEVE-2, ACHIEVE-3 and ACHIEVE-5 results, dated 2026-06-08.
What did the source report?
Lilly reported a greater HbA1c reduction in the orforglipron treatment group at 40 weeks. ACHIEVE-2 tested a small-molecule oral GLP-1 against dapagliflozin, an SGLT2 inhibitor, in adults with type 2 diabetes.
How should the results be interpreted?
Dapagliflozin is a different drug class; glucose lowering is not the only criterion for choosing diabetes therapy. Lilly reported HbA1c change up to 1.7 percentage points for orforglipron and 0.8 percentage points for dapagliflozin over 40 weeks; these are glucose measures, not body-weight percentages.
What remains uncertain?
These findings apply to the specific study, date, population, product and endpoint described in the primary source. The source may be a sponsor announcement before full peer-reviewed publication. Check the original document and current regulatory status before drawing conclusions about personal treatment. Where a study or subgroup result was first released by a manufacturer, it should not be treated as independent confirmation of every claim; compare the full protocol, population, endpoints and subsequent publications.
What does this mean for patients?
Comparative results require consideration of adverse effects and clinical indications. Treatment decisions depend on approved labeling, individual medical circumstances, availability and actual insurance benefits. MyDosePro offers educational context, not individualized prescribing or coverage confirmation.
The bottom line
Comparative results require consideration of adverse effects and clinical indications.
Written and published by MyDosePro as an educational explanation of publicly available evidence. The linked primary source is dated 2026-06-08. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceLilly ACHIEVE-2, ACHIEVE-3 and ACHIEVE-5 results ↗
Source event or update: 2026-06-08. Our interpretation is educational and does not replace medical or insurance advice.